Strategic HIV Management: Differentiating New Antiretrovirals and Designing Targeted Care Models

Program Description

Despite advances in prevention and therapy, HIV remains a leading public health challenge in the United States, with more than 1.2 million people living with HIV and approximately 30,000 new cases reported annually. Nearly 40% of individuals living with HIV are not consistently engaged in care, and only about two-thirds achieve sustained viral suppression, both of which contribute to ongoing transmission, increased health care costs, and widening care disparities among racial, ethnic, and age groups. For managed care professionals, these challenges translate into growing demands for value-based treatment selection, improved adherence support, and equitable access strategies that optimize clinical outcomes while containing costs. This session will explore updates in HIV prEP, including the latest clinical data on long-acting injectable antiretrovirals, combination regimens, and evolving guideline recommendations and real-world data on adherence and persistence. Faculty will review recent guideline updates and pivotal clinical trials to inform formulary decision-making, step-therapy sequencing, and prior authorization processes. The expert-led discussion will also highlight how pharmacists can support individualized care planning and targeted patient engagement efforts to address disparities and improve long-term viral suppression.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the evolving strategies for HIV management across the continuum of care, from prevention to treatment, and implications for optimizing patient outcomes
• Compare the recent clinical data and real-world evidence of new and emerging HIV treatment options and their roles in addressing specific gaps in the current HIV care continuum
• Explore strategies to optimize appropriate access to new and emerging HIV therapies for various patient populations, addressing barriers to care in managed care settings
  

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-086-H02-P. The activity is available for CE credit through April 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Linda M. Spooner, PharmD, BCPS, FASHP, FCCP, has no relevant financial relationships with ineligible companies to disclose.

Leana Ramirez, PharmD, AAHIVP, CSP, has the following relevant financial relationship with an ineligible company to disclose:

Advisory Board: Gilead

Pharmacy Times Continuing Education Planning Staff: Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms